FGF19 and colorectal cancer: It has been reported that the anti-FGF19 antibody 1A6 represses β-catenin activation in colorectal cancer xenograft models [26] and an engineered FGF19 (M70) inhibits FGF19-dependent tumorigenesis but retains the ability to maintain bile acid homeostasis.